GLP-1 weight loss results on TikTok: what's real vs. hype

What did @tirzedxb actually say?

Honestly, very little. The transcript from this video is: "I don't know what that's going to be. If you have it, even know what it looks like, right? Hey" That is the entirety of the spoken content. There is no identifiable medical claim, no dosing advice, no product recommendation, and no statement about GLP-1 medications that can be verified or refuted.

The video is categorized under GLP-1 receptor agonists, and the hashtags include "weightloss" and "fitness," which suggests the content is at least adjacent to the world of semaglutide, tirzepatide, or similar medications. But based purely on what was said, there is nothing to fact-check in the traditional sense. The creator appears to be mid-thought, possibly reacting to something on screen or in their environment, and the audio captured does not form a coherent claim.

Does the science back this up?

There is no claim here to test against the literature. That said, since this video lives in the GLP-1 space, it is worth briefly grounding what the actual science says about these medications, so viewers who land here have something useful to work with.

GLP-1 receptor agonists are among the most studied weight-loss interventions in recent pharmaceutical history. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide produced mean weight reductions of up to 22.5% of body weight over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4mg produced approximately 14.9% mean weight loss versus 2.4% with placebo. These are real, substantial effects, but they come with real side effect profiles, including nausea, vomiting, and potential risks like pancreatitis and gallbladder disease. No single TikTok video, including this one, is a substitute for an informed conversation with a licensed provider.

What did they get wrong (or right)?

This section cannot be completed with any confidence because the transcript does not contain a falsifiable statement. "I don't know what that's going to be" is not a medical claim. It is ambiguous, context-dependent speech that could mean almost anything.

What the video does not do, which is worth noting, is spread misinformation. No inaccurate dosing figures were given. No false equivalency between compounded and brand-name GLP-1 products was stated. No cure claims were made. In the crowded and often reckless world of weight-loss content on TikTok, the absence of harm is at least a neutral outcome.

That said, videos with hashtags like "weightloss" and "fitness" that carry GLP-1 category context do contribute to a broader information environment where viewers may be seeking guidance. The absence of clear information is its own problem when people are making decisions about prescription medications based on social media content.

What should you actually know?

GLP-1 medications are not lifestyle accessories. They are prescription drugs with clinical indications, contraindications, and side effect profiles that require medical supervision. If this video is part of a series documenting someone's personal experience with tirzepatide or semaglutide, that personal experience is valid but it is not clinical evidence, and it should not drive anyone else's treatment decisions.

A few things that matter regardless of what any TikTok video says: compounded versions of semaglutide or tirzepatide are not the same as brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has been explicit about this. Compounded drugs are not FDA-approved, and their quality, concentration, and sterility are not guaranteed in the same way. Anyone considering a GLP-1 medication should be working with a licensed provider who can assess their individual risk factors, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both of which are contraindications listed in prescribing information for these drugs.

Weight loss on GLP-1 therapy tends to plateau and reverse when medication is stopped, as shown in the STEP 4 withdrawal trial (Rubino et al., 2021, JAMA). Long-term outcomes, including cardiovascular benefit, are promising based on the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine), but this is an evolving area of research, not settled science.